Drugs in Development
All Data
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Russian Direct Investment Fund
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
After obtaining the requisite clearance from the Central Drugs Laboratory, Dr. Reddy's Laboratories and RDIF have begun adaptive phase 2/3 clinical trials for the Sputnik V vaccine in India. The trial is a multicenter and randomised controlled safety and immunogenicity study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2020
Details:
Wockhardt has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2020
Details:
AZD1222, previously known as ChAdOx1 nCoV-19, a recombinant adenovirus vaccine used against COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Serum Institute of India (SII) has filed an application with the Drugs Controller General of India (DCGI) to study a Covid-19 vaccine candidate, being developed by the UK’s University of Oxford, in Phase II and III clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
Serum Institute of India will start the trial for the vaccine candidate ChAdOx1 in a couple of weeks time, a move that comes as the researchers revealed that the initial study shows the vaccine is safe and developed antibody response in participants.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
